JP2023171909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023171909A5 JP2023171909A5 JP2023172194A JP2023172194A JP2023171909A5 JP 2023171909 A5 JP2023171909 A5 JP 2023171909A5 JP 2023172194 A JP2023172194 A JP 2023172194A JP 2023172194 A JP2023172194 A JP 2023172194A JP 2023171909 A5 JP2023171909 A5 JP 2023171909A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- nucleotide sequence
- sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721921P | 2018-08-23 | 2018-08-23 | |
| US62/721,921 | 2018-08-23 | ||
| JP2021510030A JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
| PCT/US2019/047601 WO2020041537A1 (en) | 2018-08-23 | 2019-08-22 | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510030A Division JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023171909A JP2023171909A (ja) | 2023-12-05 |
| JP2023171909A5 true JP2023171909A5 (https=) | 2024-03-06 |
| JP7541167B2 JP7541167B2 (ja) | 2024-08-27 |
Family
ID=67876086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510030A Active JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
| JP2023172194A Active JP7541167B2 (ja) | 2018-08-23 | 2023-10-03 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510030A Active JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11578127B2 (https=) |
| EP (1) | EP3840841A1 (https=) |
| JP (2) | JP7402223B2 (https=) |
| KR (1) | KR20210049863A (https=) |
| CN (1) | CN112888482B (https=) |
| AU (1) | AU2019325565B2 (https=) |
| BR (1) | BR112021003023A2 (https=) |
| CA (1) | CA3109513A1 (https=) |
| CL (2) | CL2021000437A1 (https=) |
| CO (1) | CO2021003608A2 (https=) |
| EA (1) | EA202190601A1 (https=) |
| IL (1) | IL280745B1 (https=) |
| MX (1) | MX2021002165A (https=) |
| MY (1) | MY204368A (https=) |
| PH (1) | PH12021550322A1 (https=) |
| SG (1) | SG11202101608XA (https=) |
| WO (1) | WO2020041537A1 (https=) |
| ZA (1) | ZA202100919B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3109513A1 (en) | 2018-08-23 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| US20230056380A1 (en) * | 2020-01-31 | 2023-02-23 | Randy Leiman Allen | Methods and kit for detection of analytes |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU2005282720B2 (en) | 2004-09-02 | 2011-08-04 | Genentech, Inc. | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| WO2012142286A1 (en) * | 2011-04-12 | 2012-10-18 | University Of Cincinnati | Methods for suppressing allergic reactions |
| WO2012169741A2 (ko) | 2011-06-07 | 2012-12-13 | (주)네오팜 | ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| CN104293738A (zh) | 2013-09-11 | 2015-01-21 | 李莉 | 一种抗人FcεRⅠα亚基单克隆抗体及其应用 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| SG11201701028SA (en) | 2014-08-13 | 2017-03-30 | Suppremol Gmbh | Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor |
| CN104800164B (zh) | 2015-04-13 | 2017-11-07 | 上海市第一人民医院 | 一种雷公藤免疫纳米粒及用途 |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CA3020633A1 (en) | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| CA3109513A1 (en) | 2018-08-23 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
-
2019
- 2019-08-22 CA CA3109513A patent/CA3109513A1/en active Pending
- 2019-08-22 BR BR112021003023-9A patent/BR112021003023A2/pt unknown
- 2019-08-22 KR KR1020217008580A patent/KR20210049863A/ko active Pending
- 2019-08-22 EP EP19765582.2A patent/EP3840841A1/en active Pending
- 2019-08-22 WO PCT/US2019/047601 patent/WO2020041537A1/en not_active Ceased
- 2019-08-22 MY MYPI2021000853A patent/MY204368A/en unknown
- 2019-08-22 JP JP2021510030A patent/JP7402223B2/ja active Active
- 2019-08-22 SG SG11202101608XA patent/SG11202101608XA/en unknown
- 2019-08-22 CN CN201980069380.5A patent/CN112888482B/zh active Active
- 2019-08-22 IL IL280745A patent/IL280745B1/en unknown
- 2019-08-22 EA EA202190601A patent/EA202190601A1/ru unknown
- 2019-08-22 US US16/547,910 patent/US11578127B2/en active Active
- 2019-08-22 AU AU2019325565A patent/AU2019325565B2/en active Active
- 2019-08-22 MX MX2021002165A patent/MX2021002165A/es unknown
-
2021
- 2021-02-10 ZA ZA2021/00919A patent/ZA202100919B/en unknown
- 2021-02-15 PH PH12021550322A patent/PH12021550322A1/en unknown
- 2021-02-19 CL CL2021000437A patent/CL2021000437A1/es unknown
- 2021-03-19 CO CONC2021/0003608A patent/CO2021003608A2/es unknown
-
2023
- 2023-01-12 US US18/153,522 patent/US12441797B2/en active Active
- 2023-02-13 CL CL2023000442A patent/CL2023000442A1/es unknown
- 2023-10-03 JP JP2023172194A patent/JP7541167B2/ja active Active